NUMIF - Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions | Benzinga
Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024.
The program, open to providers at the University of Utah Health and Intermountain Health, will last three years. Next, the Legislature will decide whether or not to resume it.
Physicians will be allowed to administer adult patients with psilocybin or MDMA in a medical facility. Yet the bill does not specify that hospitals can use these substances for treating conditions for which they have reached Phase 3 clinical trials – the last step before FDA approval, reported Filter Mag.
That will likely narrow down the administration of MDMA for PTSD, and psilocybin for treatment-resistant depression and major depressive disorder. It's unclear whether the new law would allow doctors prescription flexibility for treating other conditions.
Healthcare providers creating such treatment programs within their institutions must report to the legislature before July 2026 on the substances used, side effects, patients' outcomes and other information necessary for the Legislature to evaluate their medicinal value.
Some investors are expecting players in the biotech field like Numinus Wellness (OTC:NUMIF) to soon report whether they are commencing partnerships with the authorized parties in the state.
Join us for the latest updates and conversations on cannabis regulations and related discussions at our upcoming Benzinga Cannabis Capital Conference!